Episode 455: ESMO 2025 Urothelial Cancer Revi...

This podcast discusses the significance of variant histology in urothelial cancer, emphasizing the need for tailored treatment approaches based on histological features. Experts David Aggen, Tom Powles and Brian Rini explore various variant histologies, their implications for tre ...  Show more

In this podcast, Brian and Tom engage with Pedro Barata to discuss the emerging field of bispecific T cell engagers and antibody-drug conjugates (ADCs) in the treatment of prostate cancer. They explore the promising data surrounding these therapies, the challenges faced in clinic ...  Show more

Today’s episode is focusing on bladder cancer - what you need to know about the pathology, presentation, diagnostic work-up, staging, treatment, and rarer upper GU tract presentations.

We are doing a special episode this week to cover some of the key GU abstracts from ESMO 2024. We cover an update on the STAMPEDE prostate cancer trial, SUNNIFORECAST in non-clear cell renal cell carcinoma, SunRISe-4 in bladder cancer, and more.

This is the first of a two part episode on prostate cancer. This episode will cover localized prostate cancer, including the diagnostic work-up, staging and treatment. 

Hot off the press: The BOSS (Barrett’s Oesophagus Surveillance Versus Endoscopy at Need Study) randomised control study. Is surveillance really not affecting survival in oesophageal cancer patients? To put things into perspective, we asked Massimiliano Di Pietro, UEG Talks podcas ...  Show more